Andrew C. Harris

发表

Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation.

T. Braun, S. Mineishi, E. White, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine.

S. Mineishi, M. Pasquini, R. Gale, 2018, Blood advances.

A refined risk score for acute GVHD that predicts response to initial therapy, survival and transplant-related mortality

M. Robin, M. Pasquini, Richard J. Jones, 2015 .

Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation

M. Norkin, S. Choi, M. Qayed, 2021, Blood advances.

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

S. Paczesny, Bryan J Fiema, K. Lamiman, 2012, Journal of visualized experiments : JoVE.

Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality.

T. Braun, J. Greenson, E. Holler, 2013, Blood.

Advances in predicting acute GVHD

J. Ferrara, J. Levine, Andrew C. Harris, 2013, British journal of haematology.

Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth.

Nallasivam Palanisamy, Arul M Chinnaiyan, James A Connelly, 2015, JAMA.

ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.

T. Braun, S. Hanash, J. Ritz, 2013, The New England journal of medicine.

Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease.

T. Braun, S. Choi, D. Couriel, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium.

D. Porter, F. Locatelli, E. Holler, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Have we made progress in the treatment of GVHD?

J. Ferrara, J. Levine, Andrew C. Harris, 2012, Best practice & research. Clinical haematology.

FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML

T. Braun, D. Hanauer, S. Choi, 2015, Bone Marrow Transplantation.

MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.

N. Kröger, E. Holler, Y. Efebera, 2018, Blood.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

N. Kröger, F. Locatelli, E. Holler, 2017, JCI insight.

A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.

T. Braun, J. Bolaños-Meade, E. Holler, 2015, The Lancet. Haematology.

Improved accuracy of acute graft-versus-host disease staging among multiple centers.

Y. Efebera, S. Devine, W. Hogan, 2014, Best practice & research. Clinical haematology.

Ibrutinib treatment of pediatric chronic graft-versus-host disease: primary results from the phase 1/2 iMAGINE study.

G. Lucchini, K. Yoo, E. Nemecek, 2022, Transplantation and cellular therapy.

Benefits and challenges with diagnosing chronic and late acute GvHD in children using the NIH consensus criteria.

J. Chewning, G. Cuvelier, D. Coulter, 2019, Blood.

Three Biomarker Panel at Day 7 and 14 Can Predict Development of Grade II-IV Acute Graft-Versus-Host Disease

T. Braun, S. Hanash, S. Mineishi, 2010 .

A Biomarker-Based Grading System At Onset Of GvHD Predicts NRM Better Than The Modified Glucksberg Grading System

T. Braun, J. Magenau, J. Ferrara, 2013 .

Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD

M. Norkin, S. Furlan, M. Pasquini, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression.

Allen R. Chen, S. Meshinchi, M. Loken, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Extramedullary relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes

T. Braun, S. Mineishi, S. Choi, 2013, Haematologica.

Etanercept plus topical corticosteroids as initial therapy for grade 1 acute graft-versus-host disease after allogeneic hematopoietic cell transplant

T. Braun, S. Choi, S. Paczesny, 2014 .

Immune Profile Differences between Chronic GvHD and Late Acute GvHD: Results of the ABLE/PBMTC 1202 Studies.

S. Mostafavi, J. Chewning, G. Cuvelier, 2020, Blood.

Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.

K. Davis, S. Rives, A. Baruchel, 2019, The Lancet. Oncology.

Survival signal REG3&agr; prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease

M. V. D. van den Brink, J. Greenson, L. Hooper, 2018, The Journal of clinical investigation.

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry

R. Chawla, S. Grupp, S. Nikiforow, 2019, Blood.

Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.

T. Braun, S. Mineishi, S. Choi, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Survival signal REG 3 a prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease

J. Greenson, L. Hooper, Ta-Chiang Liu, 2018 .

Clofarabine and Busulfan Conditioning Facilitates Engraftment and Provides Significant Anti-Tumor Activity in Non-Remission Hematologic Malignancies Running Title: CloBu4 conditioning for HSCT

T. Braun, K. Elenitoba-Johnson, S. Mineishi, 2016 .

Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.

T. Braun, K. Elenitoba-Johnson, S. Mineishi, 2011, Blood.

Durable engraftment and excellent overall survival after CD34-selected peripheral blood stem cell boost in pediatric patients with poor graft function following allogeneic stem cell transplantation.

K. Curran, A. Scaradavou, A. Mauguen, 2022, Transplantation and cellular therapy.

Plasma biomarkers of lower gastrointestinal and liver acute GVHD.

Thomas M Braun, Sophie Paczesny, Takanori Teshima, 2012, Blood.

A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.

M. Robin, M. Pasquini, Richard J. Jones, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.

Thomas M Braun, Sophie Paczesny, Elisabeth Huber, 2011, Blood.

Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission

T. Braun, S. Mineishi, S. Choi, 2015, Annals of Hematology.

A diagnostic classifier for pediatric chronic graft-versus-host disease: results of the ABLE/PBMTC 1202 study

J. Chewning, G. Cuvelier, B. Ng, 2022, Blood advances.

Metabolomic Identification of Alpha-Ketoglutaric Acid Elevation in Pediatric Chronic Graft-versus-Host Disease.

J. Chewning, G. Cuvelier, A. Kariminia, 2021, Blood.

Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621

M. Loh, M. Borowitz, M. Devidas, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of Cryopreservation on Extracorporeal Photopheresis (ECP)-Treated Leukocyte Subsets.

J. Phillips, D. Couriel, Andrew C. Harris, 2023, Transplantation and cellular therapy.

T Cell Costimulation Blockade with Abatacept Nearly Eliminates Early Severe Acute Graft Versus Host Disease after HLA-Mismatched (7/8 HLA Matched) Unrelated Donor Transplant, with a Favorable Impact on Disease-Free and Overall Survival

M. Norkin, M. Pasquini, S. Choi, 2017 .

Evaluation of CD22 modulation as a mechanism of resistance to inotuzumab ozogamicin (InO): Results from central CD22 testing on the Children’s Oncology Group (COG) phase II trial of INO in children and young adults with CD22+ B-acute lymphoblastic leukemia (B-ALL).

M. Loh, M. Borowitz, M. Devidas, 2020 .

Using CD19 chimeric antigen receptor‐T cell therapy in a 4‐month‐old patient with infantile acute lymphoblastic leukemia

M. Boyer, Andrew C. Harris, D. Shyr, 2020, Pediatric blood & cancer.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

N. Kröger, F. Locatelli, E. Holler, 2018, JCI insight.

T Cell Costimulation Blockade with CTLA4-Ig (Abatacept) for Acute Gvhd Prevention in HLA Matched and Mismatched Unrelated Donor Transplantation: Results of the First Phase 2 Trial

M. Norkin, M. Pasquini, M. Tighiouart, 2019, Biology of Blood and Marrow Transplantation.

Extramedullary Relapse In Acute Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors And Outcomes

T. Braun, S. Mineishi, G. Yanik, 2010 .

Higher Abatacept Exposure Decreases Acute GVHD Risk Without Increasing Adverse Events.

D. Neuberg, S. Choi, B. Blazar, 2023, Blood.

ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.

T. Braun, S. Hanash, J. Ritz, 2013, The New England journal of medicine.

Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease.

T. Braun, S. Choi, D. Couriel, 2017, Biology of Blood and Marrow Transplantation.

Impact of Dose Intensification of FluBu2 to FluBu4 on Transplant Related Mortality, Relapse, and Survival After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia in Remission

T. Braun, S. Mineishi, S. Choi, 2013 .

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

M. Borowitz, M. Devidas, Lingyun Ji, 2019, Blood.

Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.

T. Braun, S. Choi, S. Paczesny, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.